Sun Yat-sen Memorial Hospital

Running trials

• Not yet recruiting

  DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer

  NCT07853053· Phase 1· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  RAPID for Unresectable Colorectal Liver Metastases

  NCT07919951· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma

  NCT07866612· West China Hospital· Source

• Not yet recruiting

  Automated Radiation Target Contouring and Treatment Planning Via RATA: A Multi-Center RCT

  NCT07922902· zhaoxiaohui· Source

• Not yet recruiting

  FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

  NCT07621497· Phase 2· Sun Yat-sen University· Source

• Not yet recruiting

  Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

  NCT07892274· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast

  NCT07657169· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast

  NCT07903181· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma

  NCT07827872· Phase 3· caohaotian· Source

• Recruiting

  A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

  NCT07798284· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study of ATG-201 in Adult Participants With Autoimmune Diseases

  NCT07732309· Phase 1· Antengene Biologics Limited· Source

• Recruiting

  Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07871110· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

  NCT07678593· Phase 1/2· Genfleet Therapeutics (Shanghai) Inc.· Source

• Recruiting

  Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

  NCT07796516· Phase 2· Peking University People's Hospital· Source

• Not yet recruiting

  A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

  NCT07837622· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

  NCT07747857· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window

  NCT07606807· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study

  NCT07724951· Shanghai Zhongshan Hospital· Source

• Recruiting

  Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

  NCT07586124· Phase 2· Lepu Biopharma Co., Ltd.· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

  NCT07717242· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

  NCT07604766· Phase 3· Genmab· Source

• Recruiting

  Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy

  NCT07895212· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Active, not recruiting

  Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects

  NCT07346027· Phase 1· Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

  NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  SGRT in Head and Neck Cancer Radiotherapy

  NCT07726407· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT07544056· Phase 2/3· BeBetter Med Inc· Source

• Not yet recruiting

  Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer

  NCT06365008· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

  NCT07630103· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

  NCT07518173· Phase 3· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Recruiting

  Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma

  NCT07326189· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke

  NCT07536165· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Extended Time Window Intravenous Thrombolysis Registry for Acute Ischemic Stroke

  NCT07536074· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Not yet recruiting

  Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

  NCT07474064· Phase 2· chenxu· Source

• Recruiting

  A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

  NCT07533123· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source

• Recruiting

  Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytology Whole-Slide Images

  NCT07488325· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

  NCT07281976· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

  NCT07347600· Hoffmann-La Roche· Source

• Recruiting

  Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07369882· Qunxing Li,MD· Source

• Recruiting

  Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

  NCT07371611· Phase 3· Qunxing Li,MD· Source

• Enrolling by invitation

  Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

  NCT07353294· Phase 1· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

  NCT07401537· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

  NCT07296458· Phase 3· Xijing Hospital of Digestive Diseases· Source

• Enrolling by invitation

  A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects

  NCT07324434· Phase 1· Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

  NCT07255404· Phase 2· BioNTech SE· Source

Showing 50 of 222.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer19 recruiting
• Head and neck cancer17 recruiting
• Bladder cancer16 recruiting
• Childhood cancers16 recruiting
• Liver and biliary tract cancer12 recruiting
• Stroke10 recruiting
• Ovarian cancer9 recruiting
• Triple-negative breast cancer8 recruiting
• Colorectal cancer6 recruiting
• Lung cancer6 recruiting
• Pancreatic cancer6 recruiting
• Thyroid cancer6 recruiting
• Endometrial cancer5 recruiting
• Lupus (SLE)5 recruiting
• Cervical cancer4 recruiting
• Primary biliary cholangitis4 recruiting
• Heart failure3 recruiting
• Prostate cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• IgA nephropathy2 recruiting
• Multiple myeloma2 recruiting
• Neuroblastoma2 recruiting
• Neuromyelitis optica (NMOSD)2 recruiting
• Obesity2 recruiting
• Rheumatoid arthritis2 recruiting
• Thalassaemia2 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Endometriosis1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gout1 recruiting
• Multiple sclerosis1 recruiting
• Psoriasis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Turner syndrome1 recruiting
• Type 2 diabetes1 recruiting
• Vascular dementia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Breast Phyllodes Tumors: Based on 20-year Real-world Data From China

  NCT07636096· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Terminated

  A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

  NCT07314060· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Terminated

  A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

  NCT07100938· Phase 2· BeiGene· Source

• Withdrawn

  A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

  NCT07076680· SciClone Pharmaceuticals· Source

• Completed

  A Trial of SHR7280 in Healthy Subjects

  NCT06969664· Phase 1· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

  NCT06710990· Phase 1· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection

  NCT06780059· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT06253195· Phase 1· BeOne Medicines· Source

• Completed

  A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

  NCT06221267· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Intravenous Tirofiban Versus Thrombolysis Before Mechanical Thrombectomy in Stroke

  NCT05728333· Phase 2/3· Xinqiao Hospital of Chongqing· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06092762· Phase 2· Akeso· Source

• Completed

  A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

  NCT05945927· Hoffmann-La Roche· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy

  NCT05856851· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  Artificial Intelligence-assisted Contrast-enhanced Ultrasound Diagnosis of Thyroid Nodules

  NCT05982821· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

  NCT07278830· Phase 2· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Terminated

  TCR-T Cell Therapy on Advanced Solid Tumors

  NCT05438667· Early phase 1· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer

  NCT06381895· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma

  NCT06366906· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

  NCT05811442· Phase 2· Beijing Joekai Biotechnology LLC· Source

• Completed

  A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

  NCT06685796· Phase 2· BeBetter Med Inc· Source

• Completed

  A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）

  NCT06691477· Beckman Coulter, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Terminated

  A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

  NCT05709093· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

  NCT05810948· Phase 2· argenx· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Hutchmed· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Terminated

  Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

  NCT05481645· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

  NCT06984159· Phase 3· Changchun GeneScience Pharmaceutical Co., Ltd.· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  A Trial of YPEG-rhGH in Children With Short Stature

  NCT05838885· Phase 2· Xiamen Amoytop Biotech Co., Ltd.· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

  NCT04942834· Ruijin Hospital· Source

• Completed

  Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

  NCT04497376· Beijing Anzhen Hospital· Source

• Terminated

  AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

  NCT04993391· Phase 1/2· Suzhou Junjing BioSciences Co., Ltd.· Source

• Completed

  PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

  NCT05390710· Phase 1· Laekna Limited· Source

• Terminated

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Phase 3· Hoffmann-La Roche· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

  NCT04934722· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

Showing 50 of 71.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer100 works · 16 trials
• Bladder cancer38 works · 23 trials
• Hearing loss27 works · 0 trials
• Triple-negative breast cancer24 works · 18 trials
• Metastatic breast cancer23 works · 36 trials
• Acute lymphoblastic leukaemia13 works · 2 trials
• Thyroid cancer9 works · 5 trials
• Aplastic anaemia3 works · 0 trials